ORIONS Money Stocks

[AugustaFriends]

Augusta's Current Holdings & Watch List -- updated 23 December 2010- at 2000 hours EST

Note: This will be updated daily. Updates as of 23 Dec 2010 (1900 hours EST)
My current Holdings:

1. FCEL $2.09 --- TARGET $2.65
FCEL – had a high of 2.20 today, with 4.2 million shares. For the past 5 days it had over 19 Million shares traded above the weekly 50ma. AF’s recommendation HOLD buy on dips; put stop loss at 1.90.
It has just crossed over 50ma on weekly - Longer term target is $5.00 there will be ups and downs.



2. UCBI $2.33 --- TARGET $3.50
UCBI – closed above middle bb on weekly chart—remains a HOLD.
1ST resistance at 2.60 break that we should go to $3.50



3. ZLC $4.11 --- TARGET $5.00 +
ZLC- Reached a high of 4.23 continues to target of $5.00 will evaluate next week.
alerted under $2




4. EMMS $.72 --- TARGET $1.00+
EMMS – disappointing day!! Stop loss at .66
Hold for 2-4 weeks this is going to be a January masterpiece



5. MVIS $1.92 --- TARGET $3.00 +

MVIS - interesting read: (posted by AKAPAK)

http://mirro7.blogspot.com/2010/03/microvision-stock-at-end-of-its.html



6. HERO $3.44 --- TARGET $7.00 +
Hercules has faced significant headwinds as shockwaves from the disaster in the Gulf of Mexico reached far wider than just BP. The fear over what would happen to BP in the wake of that mess led me to get bullish on the stock, and it has led some of my fellow Fools to look toward Transocean. I think Hercules could prove another stock that will rebound as the Gulf mess continues to move into the rearview.

posted 23 Dec 10 HERO -- just my 2 cents --- This a great entry price between 3.37 to 3.45 --- enter at your own risk.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58081109

HERO met the first target of 3.64 -- was downgraded 22 Dec 10 by an analyst -- IMO this remains a HOLD it is headed towards a Golden Cross break 3.65 and is clear to $7 imo. Also, it is trading above the 50ma on the weekly. Major support at 3.37 area.

AF's reccomendation; BUY and HOLD buy on dips ---






7. TGC $.65 --- TARGET $1.80
This one had a monster run in 2008 from .50 to $3.00 plus-- break .70 cents and Party is one. It recently had a Golden Cross on daily so if all plays out that's bullish for next 3-6 months. Oil / Gas prices should see a spike will help Energy Stocks



8. NWD $.0499 ---
NWD closed right on the weekly middle bb; needs to break .06 early in the week.
This a LOTTO play I have $500 in at at avg of .033 and truly think this could have a massive run.... IMO January 2011 play of the new year. Also, IMO if it does break out once you are up by 150% take out the initial investment and let the freebies run. We never know this could be .50+ in early 2011 LOTTO PLAY::: only play what you could throw away.



9. WAVX $3.94 --- Target $5.00
Alerted at 2.46 – target is $5.00. The daily chart may have a correction – however, a golden cross is approaching. 3-6 months bullish. My recommendation buy on dips.



10. IGC $.56 --- Target $5.00
Alerted at .60 – There was a huge volume on this one – no news but it was brought down under the middle bollie. Good to watch final week of 2010.



11. SPEX $.76 --- Target $1.20
SPEX hit a high of .89 – Huge volume came in after it broke .78 cents (previous high) – it was taken down at the close on a few sells. IMO this is must watch stock next week.
Alerted at .72 – The daily chart shows a potential of 1.20 – the weekly chart is indicating a reversal has begun.




My Watch List: Will be posted this weekend after a scan and input from other members of the board.

IVAN – nice day today; has a small gap below, watch for entry there. Long term indicators are bullish.


SNSS – Has started their Phase 3 – The charts indicate a Bullish trend has begun. Break .54 cents is the Major resistance. This is a Pharma stock and could get a quick run upwards. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS - News) today announced that the first patient has been randomized and dosed with blinded study treatment in its pivotal Phase 3 VALOR trial of vosaroxin, the company's lead drug candidate, in combination with cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML). The VALOR trial is a multinational, randomized, double-blind, placebo-controlled, pivotal trial which is expected to enroll 450 evaluable patients at leading sites in the U.S., Canada, Europe, Australia and New Zealand.




NOTE: I HAVE VARIOUS OTHER STOCKS BUT THE ONES ABOVE ARE THE ONE I WATCH DAILY OR ARE NEW TO MY TRADING PORTFOLIO.

SOME OF LONG TERM STOCKS: ACLS CPE AAU WRES
please if you have any suggestion on how you all can track my plays please let me know.